Valuation: Avenue Therapeutics, Inc.

Market Cap 857K 752K 700K 642K 1.21M 82.5M 1.23M 8.31M 3.25M 40.56M 3.22M 3.15M 140M P/E 2024
-0.22x
P/E 2025 -0.73x
Enterprise Value -2M -1.76M -1.63M -1.5M -2.81M -192M -2.86M -19.38M -7.57M -94.61M -7.5M -7.34M -327M EV / Sales 2024
-
EV / Sales 2025 -491,128x
Free-Float
86.49%
Yield 2024 *
-
Yield 2025 -
1 day+46.67%
1 week+76.00%
Current month+57.14%
1 month+37.50%
3 months-20.00%
6 months+8.75%
Current year-35.31%
1 week 0.26
Extreme 0.26
0.44
1 month 0.25
Extreme 0.25
0.44
Current year 0.15
Extreme 0.15
0.79
1 year 0.15
Extreme 0.15
0.97
3 years 0.15
Extreme 0.15
87
5 years 0.15
Extreme 0.15
2,238.75
10 years 0.15
Extreme 0.15
13,882.3
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2022
Chief Executive Officer 36 31/03/2022
Investor Relations Contact - -
Director TitleAgeSince
Chairman 71 09/02/2015
Director/Board Member 69 01/08/2015
Chairman 68 07/03/2023
Date Insider Type Main position Quantity % Market Cap.
02/01/26 FreeCompany 111,209 3.4934%
31/03/25 FreeCompany 33,724 1.6419%
31/12/24 OtherCompany 294,800 15.4214%
Change 5-day change 1-year change 3-year change Capi.($)
+46.67%+76.00%-8.33%-99.49% 857K
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+7.22%+64.67%+63.56% 56.67B
-2.15%-2.26%-21.96%-16.46% 23.28B
-0.77%-1.25%+3.33%+422.83% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%-0.63%+29.60%-32.53% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
+0.33%-0.98%+23.62%+178.38% 13.99B
Average +3.82%+0.42%+37.34%+147.10% 24.2B
Weighted average by Cap. -0.80%+1.47%+43.36%+137.02%

Financials

2024 2025
Net sales - 1.4 1.23 1.15 1.05 1.98 135.21 2.01 13.62 5.32 66.47 5.27 5.16 229.83
Net income -11.65M -10.23M -9.52M -8.73M -16.41M -1.12B -16.66M -113M -44.15M -552M -43.74M -42.8M -1.91B -2.91M -2.55M -2.38M -2.18M -4.1M -280M -4.16M -28.22M -11.02M -138M -10.92M -10.69M -476M
Net Debt -2.59M -2.28M -2.12M -1.94M -3.65M -250M -3.71M -25.16M -9.83M -123M -9.74M -9.53M -425M -2.86M -2.51M -2.33M -2.14M -4.02M -275M -4.08M -27.69M -10.82M -135M -10.72M -10.49M -467M
Logo Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Employees
1
Date Price Change Volume
23/07/26 $0.2600 -3.70% 102
22/07/26 $0.2700 +3.85% 17,006
21/07/26 $0.2600 +4.00% 3,558
16/07/26 $0.2500 -3.85% 3,208

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATXI Stock